We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Agenus (AGEN - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Agenus is one of 889 companies in the Medical group. The Medical group currently sits at #8 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Agenus is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for AGEN's full-year earnings has moved 140.7% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, AGEN has moved about 32.8% on a year-to-date basis. At the same time, Medical stocks have lost an average of 7.3%. This shows that Agenus is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Align Technology (ALGN - Free Report) . The stock has returned 8% year-to-date.
For Align Technology, the consensus EPS estimate for the current year has increased 4.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Agenus belongs to the Medical - Biomedical and Genetics industry, which includes 433 individual stocks and currently sits at #148 in the Zacks Industry Rank. This group has lost an average of 1.6% so far this year, so AGEN is performing better in this area.
In contrast, Align Technology falls under the Medical - Dental Supplies industry. Currently, this industry has 13 stocks and is ranked #63. Since the beginning of the year, the industry has moved -7.6%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Agenus and Align Technology as they could maintain their solid performance.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Agenus (AGEN - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Agenus is one of 889 companies in the Medical group. The Medical group currently sits at #8 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Agenus is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for AGEN's full-year earnings has moved 140.7% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, AGEN has moved about 32.8% on a year-to-date basis. At the same time, Medical stocks have lost an average of 7.3%. This shows that Agenus is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Align Technology (ALGN - Free Report) . The stock has returned 8% year-to-date.
For Align Technology, the consensus EPS estimate for the current year has increased 4.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Agenus belongs to the Medical - Biomedical and Genetics industry, which includes 433 individual stocks and currently sits at #148 in the Zacks Industry Rank. This group has lost an average of 1.6% so far this year, so AGEN is performing better in this area.
In contrast, Align Technology falls under the Medical - Dental Supplies industry. Currently, this industry has 13 stocks and is ranked #63. Since the beginning of the year, the industry has moved -7.6%.
Going forward, investors interested in Medical stocks should continue to pay close attention to Agenus and Align Technology as they could maintain their solid performance.